Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C

Basit Öğe Kaydı
dc.contributor.authorKokoglu, OF
dc.contributor.authorUçmak, H
dc.contributor.authorHosoglu, S
dc.contributor.authorCetinkaya, A
dc.contributor.authorKantarceken, B
dc.contributor.authorBuyukbese, MA
dc.contributor.authorIsik, IO
dc.date.accessioned2024-04-24T17:11:32Z
dc.date.available2024-04-24T17:11:32Z
dc.date.issued2006
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground and Aim: Hepatitis C virus (HCV) is prevalent in hemodialysis (HD) patients. These patients experience more side-effects with antiviral treatment. The aim of the present study was to evaluate the efficacy and tolerability of pegylated interferon (PEG-IFN) alpha-2a in chronic hemodialysis patients with chronic hepatitis C. Methods: Twenty-five patients were included into the study. All of the patients were interferon naive, anti-HCV antibodies positive and polymerase chain reaction HCV-RNA positive. Twelve of the patients received PEG-IFN alpha-2a at a dose of 135 mu g weekly for 48 weeks (Group 1). The remaining 13 patients who received no specific treatment were used as controls (Group 2). The patients were prospectively followed up for a period of 18 months. Biochemical and virological responses were evaluated at the end of the study period (end-of-treatment response) and 6 months after the completion of therapy (sustained response). Results: Virological end-of-treatment response was observed in 10 patients (83.4%) in Group 1 and one patient (7.7%) in Group 2 (P < 0.001). Sustained virological response was observed in nine patients (75%) in Group 1 and one patient (7.7%) in Group 2 (P < 0.001). Alanine aminotransferase (ALT) levels were initially increased in seven patients in Group 1 and normalized in five of these patients at the end of the treatment and sustained biochemical response was 71.4%. In contrast, ALT levels in Group 2 were initially high in five patients and normalized in two of them (40%) at the end of the 48 weeks. Even if most of the patients experienced several side-effects (anemia 75%, fatigue 58.3%, thrombocytopenia 33.3% and leukopenia 33.3%), they did not impose the discontinuation of the treatment. Conclusion: The present study showed that PEG-IFN alpha-2a for 48 weeks is efficacious and well tolerated in hemodialysis patients with HCV. (C) 2005 Blackwell Publishing Asia Pty Ltd.en_US
dc.identifier.doi10.1111/j.1440-1746.2005.04008.x
dc.identifier.endpage580en_US
dc.identifier.issn0815-9319
dc.identifier.issn1440-1746
dc.identifier.issue3en_US
dc.identifier.pmid16638102
dc.identifier.scopus2-s2.0-33645034186
dc.identifier.scopusqualityQ1
dc.identifier.startpage575en_US
dc.identifier.urihttps://doi.org/10.1111/j.1440-1746.2005.04008.x
dc.identifier.urihttps://hdl.handle.net/11468/17588
dc.identifier.volume21en_US
dc.identifier.wosWOS:000236035300015
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofJournal of Gastroenterology and Hepatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChronic Hepatitis Cen_US
dc.subjectChronic Renal Failureen_US
dc.subjectDialysisen_US
dc.subjectPegylated Interferonen_US
dc.subjectTolerabilityen_US
dc.titleEfficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis Cen_US
dc.titleEfficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu